Stockreport

Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition [Yahoo! Finance]

Repare Therapeutics Inc. - Common Shares  (RPTX) 
PDF clinical-stage precision oncology company, and Debiopharm ( www.debiopharm.com ), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's [Read more]